The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates

Molecular Pharmacology

Volumn 71, Issue 6, 2007, Pages 1610-1617

  Groner, Efrat ^a   Ashani, Yacov ^b   Schorer Apelbaum, Donna ^a   Sterling, Jeffrey ^c   Herzig, Yaacov ^c   Weinstock, Marta ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c TEVA PHARMACEUTICALS   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOINDAN; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; PHENETHYLAMINE; RASAGILINE; RIVASTIGMINE; SELEGILINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CARBAMOYLATION; CONFORMATIONAL TRANSITION; DRUG INHIBITION; DRUG STRUCTURE; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME KINETICS; IN VITRO STUDY; PARKINSON DISEASE; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; BUTYRYLCHOLINESTERASE; CARBAMATES; HUMANS; INDANS; INHIBITION (PSYCHOLOGY); INHIBITORY CONCENTRATION 50; KINETICS; MONOAMINE OXIDASE INHIBITORS; PHENYLCARBAMATES; SELEGILINE;

EID: 34347328257     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.033928     Document Type: Article

References (33)

1. Ashani Y, Snyder SL, and Wilson IB (1972) Inhibition of cholinesterase by 1,3,2-dioxaphosphorinane 2-oxide derivatives. Biochemistry 11:3518-3523.
2. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, and Silman I (2002) Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 41:3555-3564.
3. Barak D, Ordentlich A, Kaplan D, Kronman C, Velan B, and Shafferman A (2005) Lessons from functional analysis of AChE covalent and noncovalent inhibitors for design of AD therapeutic agents. Chem Biol Interact 157-158:219-226.
4. Bartolucci C, Perola E, Cellai L, Brufani M, and Lamba D (1999) "Back door" opening implied by the crystal structure of a carbamoylated acetylcholinesterase. Biochemistry 38:5714-5719.
5. Bartolucci C, Siotto M, Ghidini E, Amari G, Bolzoni PT, Racchi M, Villetti G, Delcanale M, and Lamba D (2006) Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-Alzheimer drug ganstigmine (CHF-2819). J Med Chem 49:5051-5058.
6. Bolognesi ML, Bartolini M, Cavalli A, Andrisano V, Rosini M, Minarini A, and Melchiorre C (2004) Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem 47:5945-5952.
7. Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, and Frautschy SA (2005) Prevention of Alzheimer's disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 26 (Suppl 1):133-136.
8. Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D, Rockwood K, and Martin E (2003) Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 17:117-126.
9. Ellin RI and Kaminskis A (1989) Carbamoylated enzyme reversal as a means of predicting pyridostigmine protection against soman. J Pharm Pharmacol 41:633-636.
10. Ellis JM (2005) Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc 105:145-158.
11. Ellman GL, Courtney KD, Andres V Jr, and Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
12. Giacobini E (2000) Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy, in Cholinesterases and Cholinesterase Inhibitors (Giacobini E ed) pp 181-227, Martin Dunitz Ltd, United Kingdom.
13. Harel M, Sussman JL, Krejci E, Bon S, Chanal P, Massoulie J, and Silman I (1992) Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis. Proc Natl Acad Sci USA 89:10827-10831.
14. Jann MW (2000) Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20:1-12.
15. Kraut D, Goff H, Pai RK, Hosea NA, Silman I, Sussman JL, Taylor P, and Voet JG (2000) Inactivation studies of acetylcholinesterase with phenylmethylsulfonyl fluoride. Mol Pharmacol 57:1243-1248.
16. Lane RM, Potkin SG, and Enz A (2006) Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9:101-124.
17. Liu J and Ames BN (2005) Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci 8:67-89.
18. Luo W, Yu QS, Kulkarni SS, Parrish DA, Holloway HW, Tweedie D, Shafferman A, Lahiri DK, Brossi A, and Greig NH (2006) Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydro furobenzofuran and methanobenzodioxepine. J Med Chem 49:2174-2185.
19. Luo W, Yu QS, Zhan M, Parrish D, Deschamps JR, Kulkarni SS, Holloway HW, Alley GM, Lahiri DK, Brossi A, et al. (2005) Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. J Med Chem 48:986-994.
20. Maruyama W, Weinstock M, Youdim MB, Nagai M, and Naoi M (2003) Antiapoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)- (3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 341:233-236.
21. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, and Nachon F (2003) Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278:41141-41147.
22. Pålhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, and Palm R (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200-1206.
23. Radić Z, Pickering NA, Vellom DC, Camp S, and Taylor P (1993) Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyryl-cholinesterase inhibitors. Biochemistry 32:12074-12084.
24. Saxena A, Redman AM, Jiang X, Lockridge O, and Doctor BP (1997) Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 36:14642-14651.
25. Shoham S, Bejar C, Kovalev E, Schorer-Apelbaum D, and Weinstock M (2007) Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 52:836-843.
26. Siderowf A and Stern M (2006) Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology 66:S80-88.
27. Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T, et al. (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 45:5260-5279.
28. Summers WK, Majovski LV, Marsh GM, Tachiki K, and Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315:1241-1245.
29. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, and Silman I (1991) Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science (Wash DC) 253:872-879.
30. Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, and Youdim M (2003) A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 27:555-561.
31. Wetherell JR and French MC (1991) A comparison of the decarbamoylation rates of physostigmine-inhibited plasma and red cell cholinesterases of man with other species. Biochem Pharmacol 42:515-520.
32. Youdim MB and Weinstock M (2001) Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N- propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate]. Cell Mol Neurobiol 21:555-573.
33. Yu Q, Holloway HW, Flippen-Anderson JL, Hoffman B, Brossi A, and Greig NH (2001) Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J Med Chem 44:4062-4071.